- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
French Government Negotiates a Deal With Gilead for Sovaldi
Being promised a 100% reimbursement, Gilead will now make the drug available to HCV patients in France at 60% of the cost in the United States.
has negotiated a big discount for Inc's controversial new hepatitis C drug Sovaldi, under a government deal that ensures it will be fully reimbursable by health-funding schemes.
The Economic Committee for Health Products (CEPS) has fixed the price of a box of Sovaldi at 13,667 euros before tax, a reduction of 5,000 euros on the original price and "the lowest price in Europe", the Health Ministry said on Thursday.
Twelve weeks of treatment will now cost 41,000 euros ($51,373) before tax, against 56,000 euros previously.
In the United States, where Sovaldi's high price has sparked controversy and pushed up insurance companies' costs, a 12-week course costs $84,000, or $1,000 per pill.
Link to the complete report on Reuters: http://reut.rs/1BQ4Cht
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
